Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 63-69

  Matulonis, Ursula A ^a   Sharma, Sudarshan ^b   Ghamande, Sharad ^c   Gordon, Michael S ^d   Del Prete, Salvatore A ^e   Ray Coquard, Isabelle ^f   Kutarska, Elzbieta ^g   Liu, Hua ^h   Fingert, Howard ^h   Zhou, Xiaofei ^h   Danaee, Hadi ^h   Schilder, Russell J ⁱ  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Adventist Hinsdale Hospital   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d Pinnacle Oncology Hematology   (United States)

^e Bennett Cancer Center   (United States)

^f UNIVERSITÉ DE LYON   (France)

^g Lublin Oncology Center   (Poland)

^h MILLENNIUM PHARMACEUTICALS INC   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

Author keywords

Aurora A kinase; MLN8237; Ovarian cancer; Platinum refractory; Platinum resistant

Indexed keywords

ALISERTIB; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FRANCE; HUMAN; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POLAND; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SHOCK; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES; UTERINE TUBE CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AZEPINES; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES;

EID: 84865681647     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.06.040     Document Type: Article

References (30)

1. National Comprehensive Cancer Network Inc. NCCN clinical practice guidelines in oncology (NCCN guidelines): ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) 2011 2012 [Version 1]
2. H. Lin, and C.C. Changchien Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches Taiwan J Obstet Gynecol 46 2007 379 388
3. M.M. Shahzad, G. Lopez-Berestein, and A.K. Sood Novel strategies for reversing platinum resistance Drug Resist Updat 12 2009 148 152
4. A. Berkenblit, M.V. Seiden, U.A. Matulonis, R.T. Penson, C.N. Krasner, and M. Roche A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer Gynecol Oncol 95 2004 624 631
5. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
6. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study Gynecol Oncol 101 2006 436 440
7. D.G. Mutch, M. Orlando, T. Goss, M.G. Teneriello, A.N. Gordon, and S.D. McMeekin Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 2007 2811 2818
8. J. Liu, and U.A. Matulonis New advances in ovarian cancer Oncology (Williston Park) 24 2010 721 728
9. A.A. Dar, L.W. Goff, S. Majid, J. Berlin, and W. El-Rifai Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther 9 2010 268 278
10. T.M. Gritsko, D. Coppola, J.E. Paciga, L. Yang, M. Sun, and S.A. Shelley Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer Clin Cancer Res 9 2003 1420 1426
11. H. Katayama, and S. Sen Functional significance of Aurora kinase A regulatory interactions with p53-ERalpha complex in human breast cancer cells Horm Cancer 2 2011 117 124
12. W. Hu, J.J. Kavanagh, M. Deaver, D.A. Johnston, R.S. Freedman, and C.F. Verschraegen Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer Oncol Res 15 2005 49 57
13. A.A. Kulkarni, M. Loddo, E. Leo, M. Rashid, K.L. Eward, and T.R. Fanshawe DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma Clin Cancer Res 13 2007 6153 6161
14. C.N. Landen Jr., Y.G. Lin, A. Immaneni, M.T. Deavers, W.M. Merritt, and W.A. Spannuth Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients Clin Cancer Res 13 2007 4098 4104
15. S. Lassmann, Y. Shen, U. Jutting, P. Wiehle, A. Walch, and G. Gitsch Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy Clin Cancer Res 13 2007 4083 4091
16. M.G. Manfredi, J.A. Ecsedy, A. Chakravarty, L. Silverman, M. Zhang, and K.M. Hoar Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays Clin Cancer Res 17 2011 7614 7624
17. A. Cervantes, E. Elez, D. Roda, J. Ecsedy, T. Macarulla, and K. Venkatakrishnan Phase 1 Pharmacokinetic/Pharmacodynamic Study of MLN8237 - An Investigational, Oral, Selective Aurora A Kinase Inhibitor - In Patients With Advanced Solid Tumors Clin Cancer Res Jul 2 2012 [Epub ahead of print]
18. E.C. Does, R.B. Cohen, M.M. von, T.E. Stinchcombe, H. Liu, and K. Venkatakrishnan Phase 1 Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations Clin Cancer Res Jul 5 2012 [Epub ahead of print]
19. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
20. G.J. Rustin, R.C. Bast Jr., G.J. Kelloff, J.C. Barrett, S.K. Carter, and P.D. Nisen Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer Clin Cancer Res 10 2004 3919 3926
21. J.B. Vermorken, M.K. Parmar, M.F. Brady, E.A. Eisenhauer, T. Hogberg, and R.F. Ozols Clinical trials in ovarian carcinoma: study methodology Ann Oncol 16 Suppl. 8 2005 viii20 viii29
22. A.P. Mander, and S.G. Thompson Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials Contemp Clin Trials 31 2010 572 578
23. A. Chakravarty, L. Yu, J. Huck, M. Zhang, K. Burke, and K. Galvin Pharmacodynamic/pharmacokinetic/efficacy relationships of MLN8237, a small-molecule inhibitor of Aurora A kinase AACR annual meeting abstracts April 2008 [2008; Abstract 4770]
24. G. Gorgun, E. Calabrese, T. Hideshima, J. Ecsedy, G. Perrone, and M. Mani A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood 115 2010 5202 5213
25. J. Friedberg, D. Mahadevan, D. Persky, I. Lossos, J. Jung, and E. Leonard Multicenter phase II trial of MLN8237, an investigational inhibitor of aurora A kinase (AAK), in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma Ann Oncol 22 2011 iv135
26. S. Goldberg, P. Fenaux, M. Craig, E. Gyan, J. Lister, and J. Kassis Phase 2 study of MLN8237, an investigational Aurora A kinase (AAK) inhibitor in patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) Blood 116 2011 1341
27. M. Padmanabhan, T. Shea, J. Vose, C. Reeder, J. Berdeja, and K. McDonagh Phase I study of an investigational Aurora A kinase inhibitor MLN8237 in patients with advanced hematologic malignancies Blood 116 2011 1154
28. S. Sharma, R. Kurzrock, L. Gouw, S. Hong, K. Jones, and X. Zhou Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies J Clin Oncol 2011 29
29. R.B. Cohen, S.F. Jones, C. Aggarwal, Cheng J. von MM, and D.R. Spigel A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors Clin Cancer Res 15 2009 6694 6701
30. D.S. Boss, P.O. Witteveen, S.J. van der, M.P. Lolkema, E.E. Voest, and P.K. Stockman Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors Ann Oncol 22 2011 431 437